Equity Field Notes from temporal sources

[DanWebzster]

CYDY may be a take-out depending on the results of its Ph2B/3 trials.

PH2B/3 monotherapy trial will be enrolled in Q3 2018, but will have to show efficacy for 48 weeks.

This could be the biotech story of 2019.

Layman's summary of the science:

*All HIV treatments except one inhibit different steps in viral
replication

*PFE's Selzentry is the only approved HIV therapy to target the host
receptor rather than the virus

*Selzentry increases T-cell count as well as reducing viral load in
those with H-5 HIV

*CYDYs Pro 140 not only treats H-5 HIV, but may prevent it. Its longer half life has been validated by One-injection Ph1 & 2A POC
trials

*Ph3 Monotherapy study is enrolling.

*Pro 140 is also in Ph2 in GVHD

*Pro 140 may also be used in West Nile Virus